unknown
Stage
2
Investors
About
Arpeggio Biosciences develops a drug-discovery technology that reads cell transcriptional changes to screen the activity of tens of thousands of compounds across diseased and healthy cells. The platform has established strategic partnerships with major pharmaceutical companies including Pfizer, Janssen, Genentech and Novartis.
Explore Arpeggio Biosciences's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.